J P Sfakianos1, A A Hakimi2, P H Kim2, E C Zabor3, R Mano2, M Bernstein2, M Karellas4, P Russo2. 1. Urology Service, Department of Surgery, Memorial Sloan-Kettering Cancer Center, New York, NY, USA. Electronic address: sfakianj@mskcc.org. 2. Urology Service, Department of Surgery, Memorial Sloan-Kettering Cancer Center, New York, NY, USA. 3. Department of Epidemiology and Biostatistics, Memorial Sloan-Kettering Cancer Center, New York, NY, USA. 4. Division of Urologic Oncology, The Cancer Institute of New Jersey, USA.
Abstract
AIMS: To report our experience on surgical resection of renal tumors for patients with a history of chronic anticoagulation (ACT) or aspirin use. METHODS: We performed a retrospective analysis of 2473 patients who underwent surgery for renal tumors between 2005 and 2012. Prior to surgery, 172 were on chronic ACT and 695 on aspirin. Multivariable linear and logistic regression models were used to compare transfusion and overall complication rates between patients undergoing renal surgery who were on therapy to patients who were on aspirin and to patients with no therapy. RESULTS: Compared to no therapy and aspirin patients those on ACT were older (57.3 (IQR 48.4-66.10) vs 63.9, (IQR 57.3-71.5) vs 68.4, (IQR 60.4-73.5); p < 0.001), with a higher percentage having an ASA score of 3 or 4 (42.4 vs 57.9 vs 82.6%; p < 0.001), respectively. ACT patients had a higher 30-day transfusion rate, 22.7% vs 7.6% vs 6.9%, and 90-day complication rate, 17.4% vs 7.2% vs 7.3%, both p < 0.001. The median length of stay differed statistically between groups (p < 0.001), with a modest longer stay in the anticoagulation group (OR 1.11 SE 0.26; p < 0.001). Transfusion and complication rates for patients on therapy undergoing minimally invasive surgery vs open surgery were not statistically different. CONCLUSIONS: Patients on chronic ACT had higher transfusion and overall complication rates compared to patients on no treatment or on chronic aspirin. These findings did not correlate to clinical differences in length of stay or grade 3-5 complications.
AIMS: To report our experience on surgical resection of renal tumors for patients with a history of chronic anticoagulation (ACT) or aspirin use. METHODS: We performed a retrospective analysis of 2473 patients who underwent surgery for renal tumors between 2005 and 2012. Prior to surgery, 172 were on chronic ACT and 695 on aspirin. Multivariable linear and logistic regression models were used to compare transfusion and overall complication rates between patients undergoing renal surgery who were on therapy to patients who were on aspirin and to patients with no therapy. RESULTS: Compared to no therapy and aspirinpatients those on ACT were older (57.3 (IQR 48.4-66.10) vs 63.9, (IQR 57.3-71.5) vs 68.4, (IQR 60.4-73.5); p < 0.001), with a higher percentage having an ASA score of 3 or 4 (42.4 vs 57.9 vs 82.6%; p < 0.001), respectively. ACT patients had a higher 30-day transfusion rate, 22.7% vs 7.6% vs 6.9%, and 90-day complication rate, 17.4% vs 7.2% vs 7.3%, both p < 0.001. The median length of stay differed statistically between groups (p < 0.001), with a modest longer stay in the anticoagulation group (OR 1.11 SE 0.26; p < 0.001). Transfusion and complication rates for patients on therapy undergoing minimally invasive surgery vs open surgery were not statistically different. CONCLUSIONS:Patients on chronic ACT had higher transfusion and overall complication rates compared to patients on no treatment or on chronic aspirin. These findings did not correlate to clinical differences in length of stay or grade 3-5 complications.
Authors: Ioannis M Varkarakis; Soroush Rais-Bahrami; Mohamad E Allaf; Guilherme C Lima; Sompol Permpongkosol; Pravin Rao; Thomas W Jarrett; Louis R Kavoussi Journal: J Urol Date: 2005-09 Impact factor: 7.450
Authors: Mario Sofer; James D Watterson; Timothy A Wollin; Linda Nott; Hassan Razvi; John D Denstedt Journal: J Urol Date: 2002-01 Impact factor: 7.450
Authors: Ahmad Shabsigh; Ruslan Korets; Kinjal C Vora; Christine M Brooks; Angel M Cronin; Caroline Savage; Ganesh Raj; Bernard H Bochner; Guido Dalbagni; Harry W Herr; S Machele Donat Journal: Eur Urol Date: 2008-07-18 Impact factor: 20.096
Authors: James D Watterson; Andrew R Girvan; Anthony J Cook; Darren T Beiko; Linda Nott; Brian K Auge; Glenn M Preminger; John D Denstedt Journal: J Urol Date: 2002-08 Impact factor: 7.450
Authors: David A Rhodes; Erik P Severson; Jeffrey T Hodrick; Harold K Dunn; Aaron A Hofmann Journal: Clin Orthop Relat Res Date: 2010-01 Impact factor: 4.176